for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFR) non-small cell lung cancer (NSCLC) who have received prior systemic therapies, ...

Researchers have used microcellular "drones" to deliver antisense oligonucleotide therapeutics to lung cancer cells.

See also Can sugary drinks cause cancer? “Mutant Epidermal Growth Factor Receptors (EGFRs) are the most common drivers of ...

Lung cancer, specifically Non-Small Cell Lung Cancer (NSCLC)-the most common subtype of cancer contracted by patients who do not smoke, is a leading ...

A live webcast of the presentation will be available on the Events and Presentations section of Bicara’s website at www.bicara.com. An archived replay of the webcast will be available for ...

In a study led by researchers at the NUS Yong Loo Lin School of Medicine, extracellular vesicles loaded with customizable ...

Dizal has submitted sunvozertinib’s new drug application (NDA) to the US Food and Drug Administration (FDA) aiming to secure ...

Dizal seeks US FDA approval for sunvozertinib to treat relapsed or refractory NSCLC with EGFR Exon 20 insertion mutations: Shanghai, China Saturday, November 9, 2024, 17:00 Hrs [I ...

e公司讯，迪哲医药(688192)11月8日晚间公告，近日，公司已向美国食品药品管理局(FDA)递交舒沃替尼片的新药上市申请，用于既往经含铂化疗治疗时或治疗后出现疾病进展，并且经FDA批准的试剂盒检测确认，存在表皮生长因子受体(EGFR)20号外显子插入突变(Exon20ins)的局部晚期或转移性非小细胞肺癌(NSCLC)的成人患者。舒沃替尼成为首款向美国FDA递交新药上市申请的中国源创肺癌靶向药 ...

Minghui Pharmaceutical has reported promising initial outcomes from its Phase I trial of MHB039A to treat patients with ...